Table 1:

Demographic and clinical data of seven patients with MIE

PatientAge/SexUnderlying DiseaseDrug Dosage (g)/Duration (days)SymptomsMedication Duration Before Symptom Development (days)Time to Clinical Improvement after Drug Discontinuation (days)Duration Between Symptom Onset and Initial MRI (days)Duration Between Drug Discontinuation and Follow-Up MRI (days)a
149/MCrohn disease135/90Weakness of extremities, dysarthria, gait disturbance521038–
270/MBrain abscess, LC57/38Weakness of extremities, dysarthria227714
364/MIntraabdominal abscess37.5/25Dysarthria, gait disturbance, visual blurring1771717
454/MSpontaneous bacterial peritonitis, LC49.5/33Dysarthria, confusion15521–
571/MDM foot, CRF66/44Dysarthria, gait disturbance374334
655/MIschemic colitis, LC21/14Dysarthria, gait disturbance, tingling sensation of both extremities117315
761/FPseudo-membranous colitis40.5/27Dysarthria, gait disturbance2475–
  • Note:—LC indicates liver cirrhosis; CRF, chronic renal failure; DM, diabetes mellitus.

  • a Follow-up MR imaging was not studied in 3 patients (patients 1, 4, and 7).